Published in Liver on December 01, 1983
D-penicillamine for primary biliary cirrhosis. Gut (1985) 0.83
Liver transplantation and primary biliary cirrhosis. Postgrad Med J (1989) 0.78
Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget (2015) 0.76
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology (1992) 2.82
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol (2001) 2.71
The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 2.37
Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (1998) 2.23
Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum (1995) 2.15
Screening of subclinical hepatic encephalopathy. J Hepatol (2000) 1.96
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut (1997) 1.88
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
Early cirrhosis--or primary cholangitis? Lancet (1997) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.72
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Quantitative analysis of bile acids in serum and bile, using gas--liquid chromatography. Clin Chim Acta (1974) 1.63
Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (1995) 1.57
Hepatitis B vaccination and preterm infants. Pediatr Infect Dis J (1993) 1.55
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat (2003) 1.53
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant (2001) 1.50
Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol (2000) 1.49
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer (1998) 1.49
What is the optimal time window in symptom analysis of 24-hour esophageal pressure and pH data? Dig Dis Sci (1994) 1.45
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine (1997) 1.44
Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology (1991) 1.44
The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol (2000) 1.44
Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur J Gastroenterol Hepatol (1997) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol (2000) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 1.38
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38
A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther (1998) 1.38
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res (1993) 1.37
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother (1994) 1.36
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther (1998) 1.36
The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer (1996) 1.35
Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen. Gut (1976) 1.35
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol (1994) 1.31
Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology (1997) 1.30
Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol (1994) 1.30
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations. Br Med J (Clin Res Ed) (1984) 1.25
Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol (1999) 1.21
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1999) 1.21
Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol (1998) 1.20
Behaviour of e antigen and antibody during chronic active liver disease. Relation to HB antigen-antibody system and prognosis. Lancet (1976) 1.20
Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology (1976) 1.18
Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther (2006) 1.18
Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis. Gut (1976) 1.18
Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis. BMJ (1995) 1.16
Hepatitis B reactivation after lamivudine. Lancet (1995) 1.15
Auxiliary partial liver transplantation for end-stage chronic liver disease. N Engl J Med (1988) 1.14
Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B: comparison of two solution hybridization assays. J Med Virol (1993) 1.13
Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet (1985) 1.12
Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone. Gastroenterology (1976) 1.10
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut (1994) 1.09
Auxiliary heterotopic liver transplantation. Transplantation (1988) 1.09
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat (2007) 1.07
Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol (1994) 1.07
Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology (1986) 1.05
Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer (1995) 1.04
Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun (2002) 1.04
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1997) 1.04
Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol (1984) 1.03
Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet (1980) 1.02
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol (1989) 1.01
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol (1998) 1.00
Subclinical hepatic encephalopathy. Semin Liver Dis (1996) 1.00
Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol (1994) 1.00
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther (2005) 0.99
Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol (1995) 0.99
The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology (1996) 0.99
Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol (2001) 0.98
Probabilities for a probabilistic network: a case study in oesophageal cancer. Artif Intell Med (2002) 0.98
Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology (1977) 0.98
The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat (2003) 0.98
Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol (1999) 0.98
Iron and inflammatory bowel disease. Aliment Pharmacol Ther (2001) 0.98
Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res (1976) 0.96
Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J Med Virol (2006) 0.96
Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol (1988) 0.96
Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf (1997) 0.95
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver (1998) 0.95
Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol (1993) 0.94
Is an acute disturbance in hepatic transport of bile-acids the primary cause of cholestasis in benign recurrent intrahepatic cholestasis? Lancet (1974) 0.94
HLA determinants in chronic active liver disease: possible relation of HLA-Dw3 to prognosis. Tissue Antigens (1977) 0.94
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol (2000) 0.93
Dynamics of hepatitis B virus infection in vivo. J Hepatol (1997) 0.93